CHICAGO — At the American Association of Neurological Surgeons Annual Meeting, Todd H. Lanman, MD, FAANS, spoke about the long-term results of a prospective, randomized, controlled multicenter FDA-approved clinical trial of the Prestige LP Cervical Disc (Medtronic) implanted at two adjacent levels. The low-profile titanium ceramic composite-based artificial cervical disc is indicated for single-level cervical disc disease causing nerve or spinal cord compression from C3 to C7, and is pending FDA premarket approval for two-level use.
Lanman said 7-year data presented here showed patients who had the artificial cervical disc maintained improved clinical outcomes and segmental motion compared to patients who had the standard treatment of two-level anterior cervical discectomy and fusion.
